Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.

CONCLUSION: Our experience suggests an encouraging efficacy of nintedanib/docetaxel in patients with adenocarcinoma NSCLC pretreated with platinum-based doublet chemotherapy and immunotherapy, reinforcing the importance of an optimal therapeutic sequence for managing advanced lung adenocarcinoma. PMID: 30771085 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30771085?dopt=Abstract

Source: Clinical Lung Cancer - February 15, 2019 Category: Cancer & Oncology Authors: Corral J, Majem M, Rodríguez-Abreu D, Carcereny E, Cortes ÁA, Llorente M, López Picazo JM, García Y, Domine M, López Criado MP Tags: Clin Transl Oncol Source Type: research